Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Reddy’s Launches Second US Vascepa Rival As Supreme Court Rejects Amarin

Appeal Refused In Litigation Involving Reddy’s And First-To-Market Hikma

Executive Summary

Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.

You may also be interested in...



Hikma Raises Expectations For 2021 After A Host Of Launches

On the back of a string of launches in 2021 – including the full introduction to the US market of its generic rival to Advair – Hikma has raised its full-year forecast for its generics business in anticipation of a healthy second half.

Hikma And Reddy’s Tell Supreme Court To Throw Out Vascepa Appeal

Certiorari review of a Federal Circuit decision invalidating Vascepa patents “is not warranted,” Hikma and Dr Reddy’s Laboratories have argued, claiming that the premise of originator Amarin’s petition to the US Supreme Court is “false.”

Dr Reddy’s Accuses Amarin Of ‘Illegally’ Blocking Vascepa API Supply

Having sat on an approved Vascepa ANDA since August last year, Dr Reddy’s Laboratories has sued originator Amarin, claiming the firm has illegally cornered the market for the hard-to-manufacture active ingredient.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel